GlassScriptPhysician profile
Gurinder Sidhu
NPI 1306031315
$6,134.52
in general payments reported to CMS, 2019-2025
54 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $282 · 2021: $601 · 2022: $809 · 2023: $1,487 · 2024: $1,030 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.68 |
| Education | $219.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $684.74 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $514.88 | 2021-2025 | Rybrevant, Erleada, Balversa |
| Pfizer INC. | $434.95 | 2019-2025 | |
| Amgen INC. | $366.63 | 2021-2025 | Kyprolis, Blincyto, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $324.41 | 2020-2024 | Opdivo, Augtyro |
| Lilly USA, LLC | $309.89 | 2019-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $294.91 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Genentech USA, INC. | $283.94 | 2019-2025 | Polivy, Phesgo, Tecentriq |
| Genzyme Corporation | $236.30 | 2020-2025 | |
| Abbvie INC. | $219.92 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $209.30 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $190.02 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Kyowa Kirin, INC. | $175.39 | 2022-2025 | |
| Astellas Pharma US INC | $147.89 | 2019-2025 | Vyloy, Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $135.66 | 2023-2024 |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurinder Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.